Effect of low-dose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial
Young-Il Jo, Ha-Young Na, Ju-Young Moon, Sang-Woong Han, Dong-Ho Yang, Sang-Ho Lee, Hyeong-Cheon Park, Hoon-Young Choi, So-Dug Lim, Jeong-Hae Kie, Yong-Kyu Lee, Sug-Kyun Shin
Korean J Intern Med. 2016;31(2):335-343. Published online 2016 Feb 15 DOI: https://doi.org/10.3904/kjim.2014.266
Citations to this article as recorded by 
Non-immunosuppressive treatment for IgA nephropathy
David J Tunnicliffe, Sharon Reid, Jonathan C Craig, Joshua A Samuels, Donald A Molony, Giovanni FM Strippoli
Cochrane Database of Systematic Reviews.2024;[Epub] CrossRef
Efficacy and safety of losartan in childhood immunoglobulin A nephropathy: a prospective multicenter study
Hyesun Hyun, Yo Han Ahn, Eujin Park, Hyun Jin Choi, Kyoung Hee Han, Jung Won Lee, Su Young Kim, Eun Mi Yang, Jin Soon Suh, Jae Il Shin, Min Hyun Cho, Ja Wook Koo, Kee Hyuck Kim, Hye Won Park, Il Soo Ha, Hae Il Cheong, Hee Gyung Kang, Seong Heon Kim
Childhood Kidney Diseases.2023; 27(2): 97. CrossRef
Valsartan in Combination with Tripterygium Glycosides Protects against Chronic Nephritis via the Toll-Like Receptor 4 Pathway
Jiabao Dong, Duo Huang, Ling Jing, Mengmeng Wu, Viswanathan Pragasam
Analytical Cellular Pathology.2022; 2022: 1. CrossRef
Comparison of the effects of valsartan plus activated vitamin D versus valsartan alone in IgA nephropathy with moderate proteinuria
Liu Xiaowei, Wang Bo, Li Li, Zhang Peng
International Urology and Nephrology.2020; 52(1): 129. CrossRef
Analysis of the effect of immunosuppressive therapy on the progression of chronic kidney disease with mesangioproliferative nephritis
O N Sigitova, T Yu Kim, A V Sineglazova, G R Kamasheva, R A Nadeeva
Kazan medical journal.2020; 101(2): 175. CrossRef
Angiotensin II Type 1 Receptor Blocker, Fimasartan, Reduces Vascular Smooth Muscle Cell Senescence by Inhibiting the CYR61 Signaling Pathway
Inho Kim, Chan Soon Park, Hae-Young Lee
Korean Circulation Journal.2019; 49(7): 615. CrossRef
Flow Features of Immunoglobulin A Nephropathy Depending on Activity / Risk of Progression and Influence of Pathogenetic Therapy
Olga Nikolaevna Sigitova, Taisia Yurevna Kim, Alexandra Vladimirovna Salmakova
BioNanoScience.2019; 9(2): 495. CrossRef
24-Hour blood pressure response to lower dose (30 mg) fimasartan in Korean patients with mild to moderate essential hypertension
Hae-Young Lee, Cheol-Ho Kim, Jae-Kwan Song, Shung Chull Chae, Myung Ho Jeong, Dong-Soo Kim, Byung-Hee Oh
The Korean Journal of Internal Medicine.2017; 32(6): 1025. CrossRef
Modern classification, progression factors, treatment and outcomes of primary mesangial proliferative glomerulonephritis
O N Sigitova, T Yu Kim, R R Sharipova
Kazan medical journal.2017; 98(5): 784. CrossRef